Skip to main content
. 2021 Apr 26;16:28. doi: 10.1186/s13024-021-00448-1

Table 1.

Demographic and clinical characteristics of the Alzheimer’s disease patient group and control groups

Alzheimer’s disease Normal Control Normal range
Total
(n = 32)		 Subgroup for analysis between [18F] BCPP and [11C]PBB3 PET
(n = 16)		 [18F] BCPP PET
(n = 17)		 [11C]PBB3 PET
(n = 18)
Age (years) 71.1 ± 8.3 71.3 ± 5.4 66.6 ± 9.4 69.5 ± 8.8
Men/women (number) 11/21 4/12 10/7 8/10
Disease duration (years) 2.8 ± 1.1 2.4 ± 0.8
Clinical Dementia Rating (0/0.5/1) 0/20/12 0/12/4 17/0/0 18/0/0
Mini-Mental State Examination (/30) 22.2 ± 4.1 22.8 ± 3.7 27.5 ± 1.9 27.4 ± 1.9 > 23
Wechsler Memory Scale-Revise logical memory II (delayed recall) (story A and B) (/50) 5.4 ± 5.3 6.8 ± 5.8 > 11
Frontal Assessment Battery (/18) 10.1 ± 2.6 10.7 ± 2.0
Self-rating Depression Scale (/100) 36.9 ± 8.6 37.6 ± 8.3 < 60
Regional [18F] BCPP-EF standardized uptake value ratio (Braak I-II / III-IV/ V-VI ROI)

0.59 ± 0.06/

0.85 ± 0.05/

0.89 ± 0.04

0.61 ± 0.04/

0.84 ± 0.03/

0.88 ± 0.03

 0.63 ± 0.03/0.89 ± 0.02/0.93 ± 0.03
Regional [11C]PBB3 PET binding potential (Braak I-II / III-IV/ V-VI ROI)

0.25 ± 0.08/

0.38 ± 0.13/

0.31 ± 0.11

0.25 ± 0.08/

0.38 ± 0.13/

0.31 ± 0.11

0.16 ± 0.07/

0.22 ± 0.09/

0.17 ± 0.08
Regional [11C] PiB PET standardized uptake value ratio (Braak I-II / III-IV/ V-VI ROI)

1.31 ± 0.17/

1.69 ± 0.24/

1.78 ± 0.25

1.39 ± 0.17/

1.67 ± 0.25/

1.78 ± 0.24
[11C] PiB PET global cortical standardized uptake value ratio 1.88 ± 0.24 1.89 ± 0.21 < 1.4
[11C]PBB3 PET global cortical binding potential 0.38 ± 0.11 0.38 ± 0.11 0.17 ± 0.05
Cerebrospinal fluid
Total tau (pg/ml) 712.1 ± 207.2 < 1200
Phospho-tau (pg/ml) 86.7 ± 26.1 < 50

Data are presented as mean ± SD (range)

To confirm tau pathology, sixteen out of thirty-two patients completed [11C]PBB3 PET scan. The rest of sixteen patients underwent cerebrospinal fluid tests